Friday, March 4, 2016, 87 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $21.30 to $2,750,000.00.

Highlighted Stocks Traded by Insiders:

Hanmi Financial (HAFC) - FREE Research Report

Lee Joon Hyung, who is Director at Hanmi Financial, sold 5,000 shares at $22.25 on March 4, 2016. Following this transaction, the Director owned 270,697 shares meaning that the stake was reduced by 1.81% with the 5,000-share transaction.

The shares most recently traded at $22.49, up $0.24, or 1.07% since the insider transaction. Historical insider transactions for Hanmi Financial go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 4,000
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 4,000
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 4,000

The average volume for Hanmi Financial has been 263,900 shares per day over the past 30 days. Hanmi Financial has a market cap of $713.3 million and is part of the financial sector and banking industry. Shares are down 5.99% year-to-date as of the close of trading on Friday.

Hanmi Financial Corporation operates as the holding company for Hanmi Bank that provides business banking products and services in the United States. The stock currently has a dividend yield of 2.52%. The company has a P/E ratio of 13.2. Currently, there are 5 analysts who rate Hanmi Financial a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on HAFC - FREE

TheStreet Quant Ratings rates Hanmi Financial as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, solid stock price performance, increase in net income and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Hanmi Financial Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alkermes (ALKS) - FREE Research Report

Anstice David W, who is Director at Alkermes, bought 5,000 shares at $32.87 on March 4, 2016. Following this transaction, the Director owned 15,000 shares meaning that the stake was boosted by 50% with the 5,000-share transaction.

The shares most recently traded at $34.63, up $1.76, or 5.07% since the insider transaction. Historical insider transactions for Alkermes go as follows:

  • 4-Week # shares bought: 1,600
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 1,600
  • 12-Week # shares sold: 2,000
  • 24-Week # shares bought: 1,600
  • 24-Week # shares sold: 8,000

The average volume for Alkermes has been 1.7 million shares per day over the past 30 days. Alkermes has a market cap of $5.0 billion and is part of the health care sector and drugs industry. Shares are down 58.96% year-to-date as of the close of trading on Friday.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. Currently, there are 5 analysts who rate Alkermes a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALKS - FREE

TheStreet Quant Ratings rates Alkermes as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Alkermes Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Perrigo (PRGO) - FREE Research Report

Kochan Sharon, who is EVP, GM International at Perrigo, sold 1,490 shares at $125.28 on March 4, 2016. Following this transaction, the EVP, GM International owned 5,883 shares meaning that the stake was reduced by 20.21% with the 1,490-share transaction.

The shares most recently traded at $128.00, up $2.72, or 2.12% since the insider transaction. Historical insider transactions for Perrigo go as follows:

  • 4-Week # shares sold: 900
  • 12-Week # shares sold: 900
  • 24-Week # shares sold: 1,250

The average volume for Perrigo has been 1.8 million shares per day over the past 30 days. Perrigo has a market cap of $18.1 billion and is part of the health care sector and drugs industry. Shares are down 12.5% year-to-date as of the close of trading on Friday.

Perrigo Company plc, through its subsidiaries, develops, manufactures, and markets over-the-counter (OTC) consumer goods and pharmaceutical products worldwide. The stock currently has a dividend yield of 0.46%. The company has a P/E ratio of 130.3. Currently, there are 10 analysts who rate Perrigo a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PRGO - FREE

TheStreet Quant Ratings rates Perrigo as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Perrigo Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.